On June 21, 2022, Galapagos, a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines, announced it has signed a definitive agreement for an all-cash acquisition of CellPoint for an upfront payment of €125 million, with additional milestone payments up to €100 million. CellPoint is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients. Wilson Sonsini Goodrich & Rosati advised CellPoint on the transaction.

Through the acquisition of CellPoint, Galapagos gains access to an innovative, scalable, decentralized, and automated point-of-care cell therapy supply model. Developed through a strategic collaboration with Lonza, the supply model offers the potential for efficient, seven-day delivery of CAR-T therapies and avoids complex logistics, thereby addressing important limitations of current CAR-T treatments. The proprietary platform consists of CellPoint’s end-to-end xCellit workflow management and monitoring software and Lonza’s Cocoon® system, a closed, automated manufacturing platform for cell and gene therapies.

The Wilson Sonsini team that advised CellPoint on the transaction includes:

Patents and Innovations
Lou Lieto
Angel Wang
Moonkyoung Um

Technology Transactions
Farah Gerdes
Amy Foust

For more information, see Galapagos' news release.